ICU Medical (NASDAQ:ICUI) VP Virginia Ruth Sanzone Sells 4,856 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Virginia Sanzone sold 4,856 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the sale, the vice president directly owned 14,604 shares of the company’s stock, valued at approximately $2,463,548.76. The trade was a 24.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ICU Medical Trading Down 2.1%

NASDAQ:ICUI opened at $166.29 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 140.92, a price-to-earnings-growth ratio of 2.15 and a beta of 0.75. ICU Medical, Inc. has a one year low of $112.50 and a one year high of $192.85. The business has a fifty day moving average price of $166.96 and a 200-day moving average price of $144.70.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period in the previous year, the business earned $2.10 earnings per share. ICU Medical’s quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Sell-side analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ICUI. BTIG Research lifted their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. KeyCorp lifted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Finally, Needham & Company LLC upped their price target on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $192.80.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in shares of ICU Medical in the fourth quarter worth about $58,083,000. Kirr Marbach & Co. LLC IN grew its holdings in ICU Medical by 18.4% during the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after buying an additional 6,863 shares in the last quarter. F m Investments LLC increased its stake in ICU Medical by 33.3% in the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock worth $6,637,000 after acquiring an additional 11,608 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after acquiring an additional 285,648 shares during the last quarter. Finally, Reinhart Partners LLC. purchased a new stake in shares of ICU Medical during the 2nd quarter worth approximately $46,148,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.